Diagnostic Imaging's Weekly Scan: September 15 — September 21
Diagnostic Imaging
SEPTEMBER 21, 2024
Catch up on the top radiology content of the past week.
Diagnostic Imaging
SEPTEMBER 21, 2024
Catch up on the top radiology content of the past week.
JVIR
SEPTEMBER 21, 2024
Percutaneous ablation has become an accepted therapy for small renal cell carcinoma (RCC). The rate of adverse events after renal ablation is low, with hemorrhage, hematuria, and urothelial injury being the most commonly occurring events (1). This case discusses a rare, delayed adverse event after RCC cryoablation. Western Research Ethics Board - part of Western University approval was waived for this case report.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ScienceDirect
SEPTEMBER 21, 2024
Publication date: Available online 20 September 2024 Source: Clinical Radiology Author(s): Ningning Feng, Wenhao Li, Xing Yu, Yukun Ma, Jianbin Guan, Kaitan Yang, Ziye Qiu, Guozheng Jiang
JVIR
SEPTEMBER 21, 2024
To correlate pre-ablation needle biopsy-acquired histopathologic grade of LI-RADS 5 HCC to post-ablation local tumor control rate, intrahepatic distant tumor progression-free survival, and overall survival.
Advertisement
Amidst rising cancer prevalence and soaring costs, new cancer technologies and innovations are emerging to support the early detection, treatment, and surveillance of cancer. Read this guide to understand how to evaluate these solutions for your employees and members – and to learn more about the current state of coverage, clinical and cost effectiveness, and impact on quality and outcomes.
Let's personalize your content